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Kit catalogue number  960819-1-R&D 
FSL construct full name:  FSL-RFG(Maleimide)-SC2-L1 (cat# 033106-1-R&D) 
FSL short name:  FSL-RFG(Mal) 
FSL catalogue number:  033106 
Components in this kit: 
 
All reagents are sealed in a single tamper-proof outer. Keep this outer for 
protecting the reaction from light (step 11) 
 
 
1 × 1 mg of FSL-RFG(Mal) – (0.5 mmol) – supplied in a 2 mL polypropylene 
screw top vial (cat# 033106-1-R&D) 
 
 
1 × 1 mL vial of 0.1M 4MMF buffer (containing 0.1 mmol of 4-methylmorpholine 
formate in 30% IPA, pH 6.5-6.7 under a nitrogen atmosphere). Vials have 
Teflon lined lids (cat# 833913-1-R&D) 
 
 
1 × 1.5 mL empty clear screw top glass vial with PTFE liners. 
Storage 
 
Use reagents immediately once opened, dispose of unused contents. Store 
unopened kits at below 0oC, preferably at minus 18oC or below. 
 
PRODUCT DESCRIPTION 
The FSL-RFG(Maleimide) FSL Construction Kit is for 
use in creating Function-Spacer-Lipid (FSL) constructs 
for use in non-covalent cell-surface 
modification/engineering of cellular membranes, viral 
particles, liposomes, or other surfaces [1-10]. FSL-
RFG(Mal) is one of several FSL constructs with 
Reactive Functional Groups (RFG); with this construct 
having maleimide as its Function group. The semi-rigid 
Spacer in this molecule is constructed via modified 
hexapeptide unit (Gly-Gly-Ida)2 coupling to both amino 
groups of ethylenediamine and has been designed to 
ensure accessibility for target binding/external 
interactions and proper presentation of functional 
peptides at a cell or virion surface as well as imparting 
good solubility to the construct. Electrostatic repulsion 
forces of spacer’s anionic groups probably favor uniform 
distribution of the incorporated constructs on the 
membrane surface [11]. The diacyl phospholipid derived 
from unsaturated fatty acids is a prerequisite for 
spontaneous incorporation into cell membranes. This 
FSL-RFG(Maleimide) FSL Construction Kit cat # 
960819-1-R&D (includes a detailed procedure and 
contains reagents sufficient for one FSL preparation on 
a milligram scale from cysteine-containing peptides 
(Figure 1), proteins or any other thiols of biological 
interest. The effective synthetic approach is based on 
the well-known Michael nucleophilic addition to 
maleimides, which react fast and selectively with SH-
groups in the pH range 6.5-7.5 producing stable 
thioether linkages completely stable at physiological 
conditions [12-15]. The reaction half-life between 
millimolar concentrations of maleimide and thiol is 
estimated to be of the order of few seconds [14,15]; but 
more complex and heavy molecules of biochemical 
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interest interact somewhat slower even when applied in 
10-fold excess and durations of at least 2 hours are 
recommended [16]. The protocol described here is 
optimized for this kit using FSL-RFG(Mal) with generic 
peptides and addresses problems which may be 
encountered if purification of completed FSL constructs 
is required.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The features of the procedure include using:   
• volatile buffer solution based on 4-methylmorpholine 
formate/30% IPA with a pH range of 6.5-6.8 to 
minimize both reaction non-specificity and hydrolytic 
degradation of FSL-RFG(Mal); the buffer also 
proved to be an excellent solvent for FSL-RFG(Mal), 
the vast majority of FSL constructs (II) and parent 
middle-sized peptides studied so far.  
 
 
• a 100% molar excess of >95% HPLC pure cysteine-
containing peptides or sulfhydryl-haptens over FSL-
RFG(Mal) – see also Application Note #1 
• straight forward removal of residual peptides during 
cell washing step following FSL construct 
incorporation or direct purification of constructs by 
simple re-precipitation 
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Figure 1: Formation of FSL-peptide construct (II) via ligation of reactive maleimide moiety of 
FSL-RFG(Mal) (I) to thiol function of cysteine incorporating peptide.  
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METHOD OVERVIEW (minimal procedure - Step relate directly to steps in the following method notes) 
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METHOD 
 
NOTE: Read peptide consideration notes (below) before 
selecting peptides for ligation 
  
1. Weigh a quantity of peptide (HPLC purity 
>95%) corresponding to 1 mmol (100% molar 
excess with respect to FSL-RFG(Mal) – 
Application Note #1) into the empty transparent 
1.5 mL glass vial supplied.  
2. Dissolve the peptide in minimal volume of 4-
MMF buffer from a freshly opened vial starting 
from 100 mL (Application Note #2).  
3. Sonicate until a clear solution is obtained and if 
required centrifugate briefly to 
remove/recover/utilize any material adhered to 
the tube walls. Complete dissolution of peptide 
is pre-requisite for successful ligation. If 
peptide is still not solubilized after 10 minutes 
in an ultrasonic bath, and the addition of further 
200 mL of 0.1 M 4MMF is not helpful you may 
need to use one of the organic co-solvents as 
described in Application Note #2.  
4. Reconstitute the vial of FSL-RFG(Mal) reagent 
(0.5 mmol) with 100 mL of 4-MMF from the 
freshly opened vial.  
5. Sonicate or vortex for 1 minute. Use 
immediately.  
6. Immediately transfer with a pipette the peptide 
solution to the reconstituted FSL-RFG(Mal). 
7. Rinse the peptide tube with 100 mL of buffer, 
briefly sonicate  
8. Transfer the rinsing’s to the FSL-RFG(Mal) vial 
and firmly replace the cap.  
9. Sonicate the reaction mixture for 10 mins (but 
no longer than 60 mins) in an ultrasonic bath. 
10. Incubate the reaction mixture for 2 hours with 1 
minute sonication approximately every 30 
minutes. This step is not required if a clear 
solution is obtained, yet sometimes the 
construct partially precipitates (Application 
Note #3) and forms a cloudy solution or fine 
suspension. 
11. Incubate the reactants overnight at room 
temperature (protected from direct light). To 
protect from light preferably use the outer 
plastic container (with lid) the kit was supplied 
in, or use aluminum foil.  
12. Optionally quench any unreacted maleimide 
(See Application Note #4) 
13. Dry the reactants in a vacuum centrifuge. (See 
Application Note #5). Alternatively you may 
freeze-dry the contents after transfer to a 
larger vial, adding 500 mL of water, 
immediately freeze and lyophilize.  
14. The product should appear as a transparent 
film but if the product appears to be wet then 
redissolve with 500 mL of water, sonicate and 
dry again. 
15. Reconstitute the product (containing ~0.5 
mmol of FSL-peptide + ~0.5 mmol peptide) 
with 1 mL water. 
16. Aliquot then dry into vials. The product 
obtained will be an amorphous white powder or 
clear film that is the fully functional / ready-to-
use form of constructs II. The product should 
be stable if stored freeze-dried at -10oC or 
below for at least 10 months. Reconstituted 
product is relatively stable in saline. Solubility 
profile (see Application Note #6) 
 
The crude FSL-peptide product is virtually free from 
contaminants (see also Application note #5) other than 
residual Cys-containing peptide, and respective SS-
dimer, which will not interfere with most of the expected 
applications of the constructs. The final FSL-peptide 
product will purify itself during the cell insertion process, 
as only the FSL constructs are likely to insert and 
remain in the cell membrane. However, the user may 
optionally further purify the product as follows by three 
rounds of reprecipitation. This requires completely 
dissolving the solids to remove impurities which are 
occluded/trapped inside the amorphous solid in a 
minimum of water with the help of IPA to facilitate 
wetting of the precipitate. This is followed by 
precipitation with about 10 volumes of IPA and a final 
EtOH wash, which efficiently removes the residual IPA 
with dissolved impurities (in practice, alcohol-soluble 
constructs are occasionally encountered; these should 
be precipitated with neat acetonitrile). At least one re-
precipitation round should be carried out according to 
recommendations below to remove traces of any 
occluded/co-precipitated non-peptide material.  
 
Optional further purification 
1. Sonicate the dry residue twice with IPA (100 
mL) until a fine suspension is obtained and 
centrifuge. The FSL-peptide constructs should 
be in the precipitate. Do not discard the 
supernatants but transfer them to a 10 mL 
clean vial marked “Combined Washes” 
(Application Note #7).  
2. Dissolve the precipitate in minimal volume of 
water (1 drop) and precipitate it with 1 mL of 
IPA. Centrifugate and decant the supernatant 
to “Combined Washes”. Wash the precipitate 
twice with 100mL of EtOH and transfer 
supernatant to “Combined Washes”. Repeat 
this wash step one further time. Transfer all 
supernatants to vial marked “Combined 
Washes. 
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3. Dissolve the final precipitate (expected to 
contain the FSL constructs) in 1 mL of water 
and freeze dry or vacuum centrifuge.  
4. As a safeguard, we recommend to dilute 
Combined Washes with 2-3 volumes of water 
and lyophilize. The dry residue normally 
contains unreacted peptide material and minor 
by products, yet occasionally may retain 
considerable amounts of FSL constructs. The 
latter could be recovered via re-precipitation 
using alternative solvents (see Application 
Note #6). 
5. At your convenience reconstitute the product 
with water and aliquot as necessary before 
final freeze-drying. Product may be unstable in 
water (at pH above 7, in particular) so 
lyophilize immediately after reconstitution. The 
product obtained will be an amorphous white 
powder that is fully functional /ready to use 
form of constructs II. It should be stable upon 
storage at -10oC or below for at least 10 
months. Reconstituted product is relatively 
stable in saline. Solubility profile (see 
Application Note #6). 
 
Chemically defined water-soluble FSL constructs 
produced in this way can be purified by repeated 
precipitation and characterized using ESI MS in 
negative mode and 1H-NMR spectroscopy (see 
Application Note #10).  
 
Reagents and Equipment Required but Not 
Provided (excluding optional steps)  
Ultrasonic bath/sonicator; Freeze-dryer or Vacuum 
Centrifuge 
 
Precautions and Disclaimer This product is for R&D 
use only, not for drug, household, or other uses. Please 
consult the Material Safety Data Sheet for information 
regarding hazards and safe handling practices.  
  
 
PEPTIDE CONSIDERATIONS FOR 
CONSTRUCTION INTO FSL-PEPTIDES  
Once candidate peptide sequences have been 
identified, they should be refined to find those most 
likely to be compatible with, and successful as, an FSL 
construct. Some of these issues relate to the peptide 
[19,20] while others are specific to FSL chemistry. Many 
of the issues and characteristics of proteins/ 
peptides/amino acids [21-28] can be identified by using 
existing algorithms/rules as found in resources such as: 
I-Tasser [29], BLAST [30], Immune Epitope Database 
(IEDB, www.iedb.org) [31], hydrophilicity [32], 
secondary structure [23], B-cell epitope [33], flexibility 
[34], surface accessibility [35], N-glycosylation [37], O-
glycosylation [37], etc. 
Specific issues in the design and construction of peptide 
based FSLs include those listed below. These issues for 
consideration, where possible should be mitigated for, 
or compromises found. However in many cases they 
have to be simply accepted as risks, with the outcome 
ultimately determined by success in both synthesis and 
biology. 
Peptide length - In theory the minimum number of 
amino acids required for antibody recognition is 4-6 [38]. 
But in practice anything less than 12 is not 
recommended as the additional flanking amino acid 
residues may also contribute to adequate epitope 
presentation and specificity, and increase the range of 
recognition by polyclonal antibodies. 
Internal cysteine - peptide to spacer ligation chemistry is 
thiol based and a cysteine residue is used to conjugate 
peptide to the spacer (S) (Fig. 1). This is normally 
achieved by the addition of a cysteine residue to the 
final peptide sequence at either the amino or carboxyl 
ends (depending on orientation required). In principle, 
this limitation requires that cysteine(s) be absent from 
the selected peptide sequence (although this limitation 
could be resolved either via iso-steric substitution of Cys 
for α-aminobutyric acid [39], or potentially by using the 
native cysteine side chain for SL ligation).  
N-terminal glutamine - Peptides bearing N-terminal 
glutamine (Gln) are known to undergo notoriously fast 
cyclization to form pyroglutamic acid residues [40] with 
the cyclization rate being in the range ~2-3% /h under 
physiological conditions [41]. This spontaneous 
transformation is likely to effect antigenicity and should 
be excluded where the predicted epitope begins with N-
terminal Gln. Sacrificing it, or selecting peptide with an 
extra residue preceding Gln will remove this potential 
complication. 
 
Fig. 2 Cyclization of N-terminal glutamine resulting in 
undesired pyroglutamic acid 
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Asparagine deamidation - Peptides incorporating 
asparagine (Asn) followed by a non-hydrophobic 
residue -Asn-Xaa- are prone to spontaneous 
deamidation via intermediate formation of 5-membered 
aspartimide, giving rise to a mixture of related α - and β 
-aspartyl peptides [42] potentially having altered 
antigenic profiles. The rate of degradation depends 
largely upon Xaa structure and is highest for Gly 
approaching ~2%/h under physiological conditions [43]. 
This type of intrinsic peptide instability is incurable by 
sequence manipulation and should be considered 
seriously. At least Asn-Gly should be excluded by all 
means while the potential problems in case of other Xaa 
should be evaluated on the basis of published data 
obtained for related model peptides [43] and 
experimental outcomes. 
  
Fig. 3 Asparagine deamidation pathways resulting in 
undesired related α - and β -aspartyl peptide 
Solubility - Perhaps the most important practical aspect 
of peptide selection focuses on detection and 
troubleshooting solubility problems associated with a 
particular sequence as such, and the related FSL 
construct. Ideally, to ensure smooth and efficient 
ligation, both should possess solubility in ligation buffer 
(0.1M 4-methylmorpholine formate in 30% isopropanol, 
pH~6.5) on the order of few mg/mL. Speaking from 
experience, we recommend avoiding sequences 
marked with the following insolubility signatures: 
• peptides either having net charge |Zpept|<2 
themselves, or yielding FSL constructs with net 
charge in that region, i.e. |Zpept-5|<2; Zpept = 
Σ(R+K+N-terminus + 0.5*H)- Σ(D+E+C-
terminus); in other words these conditions 
roughly specify molecules having pI and, 
hence, solubility minimum in physiological pH 
range. 
• sequences harboring clusters formed by non-
charged residues which include 3 or more 
consecutive I, F, Y, W, L, V, T  
In cases when solubility improvement through sequence 
manipulation is impossible, co-solvents can be used to 
solubilize peptide prior to ligation: (i) trifluoroethanol (or 
hexafluoroisopropanol, or 2-methoxyethanol) - ligation 
buffer or pyridine (1:1, v/v), (ii) neat dimethylformamide 
or (iii) 6M guanidinium hydrochloride (should be tested 
in this order) and may prove useful for dissolving those 
peptides at a concentration of few mg/mL. Dimethyl 
sulphoxide (DMSO) may promote disulfide formation 
and should not be used to dissolve Cys-containing 
peptides. The resultant FSL construct may be more 
soluble than the starting peptide and although forcing 
conditions (e.g. increasing pH with ammonium 
bicarbonate, or using initially neat DMSO, glycerol, 6M 
urea, 30-50% aqueous alcohols followed by dilution with 
application-compatible medium) can allow for 
reconstitution of poorly soluble FSL constructs. The 
most important biological applications, however, 
ultimately require FSLs constructs dispersible in saline 
alone as it is this feature that allows modification of cells 
without affecting their vitality and functionality. In this 
connection, preliminary evaluation of potential 
insolubility issues is strongly recommended to avoid 
wasting efforts on preparation of insoluble and useless 
material.  
Potential glycosylation sites - Both N- and O- potential 
glycosylation needs to be considered during the peptide 
selection process. The standard N-glycosylation 
sequence is N-X-S/T where X-could be any amino acid 
other than proline [44]. There is no single O-
glycosylation motif but it usually occurs with high 
content of serine, threonine and proline residues [36] 
and in combinations like TAPP, TVXP, S/TPXP, TSAP, 
PSP, and PST, where X is any amino acid [44]. As 
glycosylation dramatically changes the nature of an 
epitope the following strategies should be considered: 
(i) optimizing the peptide to avoid residues suspected in 
glycosylation or (ii) direct chemical synthesis of 
appropriately glycosylated peptides [45] or as a last 
resort (iii) using a naked peptide in the hope that it may 
still retain the expected binding specificity.  
Needless to say, these considerations also apply to any 
post-translational modification [46,47] in the proximity of 
the epitope sequence. 
Microbial relatedness - algorithms for comparing 
primary biological sequences to microbial sequences 
(e.g. BLAST [30], Immune Epitope Database [31]) help 
predict and evaluate the degree of potential cross-
reactivity associated with the proposed peptide. 
Avoidance of microbially related epitopes reduces the 
risk of undesired non-specific cross-reactivity from 
FSL-RFG(Mal) Technical Bulletin #20110928 
 
7 
naturally occurring antibodies directed against 
microbes.  
PREPARATION OF CELLS/VIRIONS 
MODIFIED WITH FSL-PEPTIDE 
CONSTRUCTS [1]  
Typically biological activity is obtained with peptide-
based FSL constructs in the range of 1-100 µg of FSL 
construct per mL of cell transformation solution. The 
working range dilutions will depend on the application, 
the detection method sensitivity, the diluent, the type of 
FSL construct, and the degree of modification required.  
Preparation of FSL Constructs 
i.  Prepare the FSL construct stock solution by 
reconstituting the dry FSL product by the 
addition of appropriate diluent (preferably not 
containing lipids or highly hydrophobic 
material). Briefly sonicate (30 seconds). FSL 
constructs can be diluted in water but will have 
reduced stability and must be used within 
hours. 
ii.  Prepare working FSL construct solutions for 
insertion, just prior to use. Briefly sonicate (30 
seconds) the stock solution to homogenize any 
micelles. Dilute the FSL construct in buffer 
(preferably not containing lipids or highly 
hydrophobic material) to the concentration 
required or over a range if desired. FSL 
constructs will usually insert into cells in lipid 
containing media but will typically require as 
much as a 50 × higher FSL concentrations 
than if in PBS or other lipid free media. 
 
Insertion of FSL Construct(s) into Membranes 
iii.  Wash the cells for FSL modification free of 
unbound lipids by centrifugation and using 
PBS or lipid free cell media as wash solution. 
The diluent used to suspend the cells can be 
cell culture media, PBS, cell storage solutions, 
etc, but preferably without lipids ( e.g. fetal calf 
serum) or detergents (e.g. Tween). 
iv. Suspend in 100µL of diluent. Different volumes 
(than 100µL) or ratios (than 1:1 cells/FSL 
solution) may be used provided the same ratio, 
concentration, and volume are used to obtain 
reproducible results. 
v. Add 100µL of an appropriate dilution of FSL 
solution (containing 1 or more FSL constructs) 
to the cells and incubate for 1 hour at 37°C. A 
similar result can be obtained by 6 hours 
incubation at 25ºC or overnight (18 hours) at 
4ºC – mixing is recommended every few hours 
if heavy cell suspensions are used. 
vi. Wash (optional) twice to remove any free FSL 
constructs and prepare an appropriate cell 
suspension.  
 
APPLICATION NOTES 
 
Note #1. This procedure can be done with only a 20% 
molar excess of >95% HPLC purity peptides. However, 
despite claims of >95% purity, the quality and purity of 
peptides supplied by various vendors is variable [48] 
and together with risks of cysteine residue oxidation and 
small volume weighing errors, this method advises use 
of 100% molar excess of peptide. If 100% excess is 
used then the user can be confident the reaction will go 
through to completion. 
If the user elects to use a 20% molar excess then exact 
calculation of the stoichiometric quantity of a synthetic 
cysteine-containing peptide is required. The most 
professional approach to calculate the adequate 
quantity implies spectrophotometric determination of 
actual reactive thiol content CSH in mmol HS/mg in 
peptide material to be used. Standard procedures 
employing DTNB [17] (Ellman reagent) detailed in 
Sigma Technical Bulletins D8130 and MBK1 are 
recommended. In case the determined HS-content is 
too low, the reduction of disulfide may be in order 
according to one of the available protocols [18]. Despite 
popular belief this problem could not be fixed by 
performing ligation in the presence of tributylphosphine 
or TCEP which were recently shown to react with 
maleimides [49,50]. Weight of peptide material required 
for 1 ligation (0.6 mmol, 20% molar excess) is 
calculated as W, mg = 0.6/CSH  
In case spectrophotometric quantitation of thiol content 
is not performed, the required peptide quantity could be 
calculated assuming peptide content in an average 
HPLC-purified synthetic peptide material to be 75% [48] 
as a best approximation. Within this approach the 
weight of peptide material required for 1 ligation (0.6 
mmol, 20% molar excess) is calculated as 
W, mg=0.6*1.2*MW/0.75= 0.96*MW, where MW stands 
for nominal molecular weight of the peptide (without 
counter-ions) expressed in mg/mmol.  
Note #2. Reaction buffer 0.1M 4MMF vials are supplied 
degassed and in a nitrogen atmosphere. Use a freshly 
opened vial for each ligation reaction. 
Checking the extent of peptide solubility in the ligation 
buffer before hand is strongly recommended (see 
Solubility notes above). The vast majority of middle-
sized peptides will dissolve at concentration 5-3 mg/mL 
and for these this protocol will work consistently. 
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Peptides that are not completely soluble at 1 mg/mL are 
unlikely to respond to further increasing buffer to 
peptide ratio. In many cases satisfactory results will be 
obtained with peptides insoluble in the ligation buffer at 
1mg/mL and hence need to be introduced into reaction 
dissolved in organic or chaotropic medium. The success 
of such experiments is not certain and these may be 
undertaken at user's own risk.  
Note #3. Poor solubility can be expected for constructs 
II with overall charge in the range -2 ÷ +2, i.e. those 
derived from basic peptides bearing net electric charge 
+4 ÷ +6 
Note #4. Optionally quench any residual maleimide on 
FSL-RFG(Mal) with a suitable non-interfering thiol 
(cysteine, DTT, ME, etc) before freeze drying . For 
example mix thoroughly reaction mixture with 60 mL of 
0.1M mercaptoethanol and leave it for at least 1 hour at 
room temperature to ensure complete quenching of any 
unreacted maleimide component I. 
Note #5. A simplified precipitation step may be 
introduced here to be sure that user has completely 
removed the 4-MMF salt at the end of vacuum drying. 
This salt is the least volatile component that may persist 
at the transparent film stage in the amounts harmful to 
you cells. At least single precipitation (IPA or MeCN) is 
highly desirable to ensure 4-MMF is no longer an issue. 
To do this  sonicate thoroughly the crude product 
obtained as a transparent film with 300 mL of IPA, 
decant the fine suspension thus obtained and repeat the 
IPA wash. Redissolve the wet product in a minimum 
amount of water (~50 mL) and  precipitate with 10-15 
volumes of acetonitrile, centrifugate, wash with 200 mL 
of IPA and dry in vacuum. Drying compounds II using 
Fisher apparatus at elevated temperatures, or by 
washing with copious amounts of absolute ether, albeit 
highly efficient, should be avoided since both of them 
yield over-dried material that is extremely difficult to 
reconstitute in water. 
Note #6. These recommendations are based on 
generalized solubility profile typical of constructs II 
derived from water soluble peptides: 
• Solubility in unbuffered water is about 1-5 
mg/mL and could be increased 2-3-fold by mild 
basification (ammonium bicarbonate solution, 
or pyridine); not unexpectedly, acidifying 
produce an opposite effect and precipitates II 
from an aqueous solution. The indicated pH-
dependence reflects domination of acidic 
residues in molecules of this group. However, 
the reversal of the trend should be expected 
and was actually observed for constructs 
derived from peptides bearing overall charge of 
+6 and more 
• Product may be unstable in water for extended 
periods of time, and should only be used as a 
working solution in saline solutions or solvents. 
• in 10-50% unbuffered IPA - up to 10-20 mg/mL 
(optimal % of IPA depends on sequence; this 
alcohol appeared to be most compatible with 
compounds II and should be preferred to 
MeOH & EtOH); 
• in DMSO, DMF, NMP - 10-20 mg/mL and 
above; 
• in acetone, MeCN, dioxan, THF, IPA, EtOH - 
very poor, but increases with increase of water 
content; 
• insoluble in Et2O, EtOAc, DCM and other 
solvents immiscible with water. 
Note #7. As a safeguard, collect all washes generated 
in the course of isolation and keep them combined in an 
appropriate PP tube. This precaution is necessary in a 
view of unpredictable solubility behavior of constructs II 
derived from diverse peptides, which makes impossible 
to formulate a universal isolation protocol devoid of the 
risk of discarding the desired product. In any case, a 
second crop of II could be obtained via acetonitrile 
precipitation from the vacuum-evaporated combined 
washes. 
Note #8. TLC. Presence of polyanionic spacer in I and 
its derivatives II results in anomalous chromatographic 
behavior of these compounds. They are not eluted from 
RP HPLC column under standard binary gradients of 
MeOH or MeCN, even on prolonged elution. In principle, 
at least for some peptides, TLC in one of the following 
solvent systems may be useful. 
• CHCl3/MeOH/H2O 1:3:1 (v/v+0.5% pyridine),   
• CHCl3/MeOH/H2O 2:6:1 (v/v+0.5% pyridine) 
• MeCN:MeOH:H2O, 3:3:2, v/v 
and staining with 0.3% ninhydrine in 3% AcOH-n-BuOH, 
or 7% H3PO4 in IPA  
But, in reality many peptides will require laborious 
experimental selection of optimal sequence-specific 
solvent system to obtain a clear-cut TLC pattern. The 
efficiency of the present ligation protocol resides, 
therefore, on carefully optimized reaction conditions 
rather than real-time analytical control of the reaction.  
Note #9. Spectroscopic characterization of constructs II. 
Unique but unfavorable from practical point of view 
solubility profile of II makes them not compatible with 
RP HPLC, while on the other hand, natural diversity of 
parent peptides makes potential usage of otherwise 
straightforward TLC analysis highly problematic. Using 
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modern spectroscopic techniques like NMR or MS 
generates important structural evidence for II but within 
certain reservations that need commenting. Most 
straightforward and reassuring evidence for II was 
offered so far by mass-spectrometry with ESI ionization 
specifically and in negative mode ONLY, with direct 
injection of sample solution being an extra strict 
requirement that guarantees recording most adequate 
and informative spectrum. The desired molecules II are 
represented in the latter by the expected set of clusters 
formed by multiple charged anions derived from 
molecular ion. These consistently predominate over 
minor peaks of residual SS-dimer of the starting peptide 
and secondary fragmentation peaks. Curiously, the 
latter formally correspond to masses of starting 
reagents: maleimide I and the reduced peptide thiol, the 
artifacts of retro-Michael fragmentation, which could be 
suppressed by adjusting ionization voltage of the ion 
source. Occasionally performed parallel analyses of the 
same samples using ESI and more destructive MALDI 
technique (positive mode) suggested that the latter is 
not compatible with FSL constructs since it generally 
fails to detect even traces of expected molecular ions 
and produces non-informative and misleading patterns. 
1H-NMR spectra recorded for solutions of II in 20-60% 
CD3OD/D2O could provide further qualitative support for 
the expected structure, with the low-field region (starting 
from ~4 ppm downfield) being most informative. 
Quantitation of NMR spectra in a usual way is not 
possible because formation of micelles/aggregates 
interferes with relaxation phenomenon and distorts 
integral intensities.  
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